Volume 26, Number 6—June 2020
CME ACTIVITY - Research
Statin Use and Influenza Vaccine Effectiveness in Persons ≥ 65 Years of Age, Taiwan
Table 3
Characteristics | Vaccinated |
Unvaccinated (referent) |
Hazard ratio (95% CI)† |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
No. | Person-years | Incidence‡ | No. | Person-years | Incidence‡ | Crude | Adjusted | |||
In-hospital death§ | 38,320 | 2,984,344 | 12.84 | 55,405 | 2,949,054 | 18.79 | 0.68 (0.67–0.69) | 0.69 (0.68–0.69) | ||
Statin user | 1,478 | 147,164 | 10.04 | 22,097 | 146,668 | 14.30 | 0.70 (0.66–0.75) | 0.71 (0.67–0.76) | ||
Statin nonuser |
36,842 |
2,837,180 |
12.99 |
53,308 |
2,802,386 |
19.02 |
0.68 (0.67–0.69) |
0.68 (0.68–0.69) |
||
In-hospital death from pneumonia¶ | 15,057 | 2,984,931 | 5.04 | 20,699 | 2,950,157 | 7.02 | 0.72 (0.70–0.73) | 0.72 (0.70–0.73) | ||
Statin user | 503 | 147,202 | 3.42 | 665 | 146,723 | 4.53 | 0.75 (0.67–0.85) | 0.75 (0.67–0.85) | ||
Statin nonuser |
14,554 |
2,837,730 |
5.13 |
20,034 |
2,803,435 |
7.15 |
0.72 (0.70–0.73) |
0.72 (0.70–0.73) |
||
Hospitalization for pneumonia or influenza# | 103,395 | 2,946,802 | 35.09 | 121,776 | 2,907,115 | 41.89 | 0.84 (0.83–0.84) | 0.84 (0.84–0.85) | ||
Statin user | 3,967 | 145,687 | 27.23 | 4,810 | 144,805 | 33.22 | 0.82 (0.79–0.86) | 0.82 (0.79–0.86) | ||
Statin nonuser |
99,428 |
2,801,115 |
35.50 |
116,966 |
2,762,309 |
42.34 |
0.84 (0.83–0.85) |
0.84 (0.84–0.85) |
||
Hospitalization for circulatory condition** | 394,245 | 2,801,412 | 140.73 | 430,954 | 2,750,954 | 156.66 | 0.90 (0.90–0.90) | 0.90 (0.90–0.90) | ||
Statin user | 25,141 | 134,914 | 186.35 | 27,991 | 132,843 | 210.71 | 0.89 (0.87–0.90) | 0.90 (0.88–0.91) | ||
Statin nonuser |
369,104 |
2,666,498 |
138.42 |
402,963 |
2,618,111 |
153.91 |
0.90 (0.90–0.90) |
0.90 (0.89–0.90) |
||
Hospitalization for critical illness†† | 62,018 | 2,968,927 | 20.89 | 82,602 | 2,929,804 | 28.19 | 0.74 (0.73–0.75) | 0.75 (0.74–0.76) | ||
Statin user | 2,614 | 146,432 | 17.85 | 3,574 | 145,677 | 24.53 | 0.73 (0.69–0.77) | 0.74 (0.71–0.78) | ||
Statin nonuser | 59,404 | 2,822,496 | 21.05 | 79,028 | 2,784,127 | 28.39 | 0.74 (0.73–0.75) | 0.75 (0.74–0.76) |
*Values after propensity score-matching between persons who received and did not receive influenza vaccination.
†Calculated by Cox regression model with adjusted imbalance covariates listed in Table 1. In all cases, p<0.001.
‡Per 1,000 person-years.
§Interaction p = 0.478.
¶Interaction p = 0.493.
#Interaction p = 0.138.
**Interaction p = 0.667.
††Interaction p = 0.375.
1These authors contributed equally to this study.
Page created: May 15, 2020
Page updated: May 15, 2020
Page reviewed: May 15, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.